Prana Volume Up on Phase II Trial Updates for Its PBT2 Alzheimer's Candidate
(Thomson Reuters ONE) -
Australian-listed Prana Biotechnology (ASX:PBT)(NASDAQ:PRAN) gave updates today
on the company's ongoing Phase II trials for lead compound PBT2, a potential
treatment for neurodegenerative diseases Alzheimer's and Huntington's. After a
20% rally yesterday, the stock is giving up some of those gains today and is
down 7% in late morning. Shares are moving this week at ten times normal volume
on the Australian Securities Exchange, and triple average volume on the Nasdaq.
Although too early for definitive results in the studies, Prana's approach,
which targets defects in the metabolism of biological metals, showed promise in
earlier trials and presents investors with an underexposed Alzheimer's play.
To read more about Prana Biotechnology and its ongoing trials, click here.
About PropThink
PropThink is an intelligence service that delivers long and short trading ideas
to investors in the healthcare and life sciences sectors. Our focus is on
identifying and analyzing technically-complicated companies and equities that
are grossly over or under-valued. We offer daily market coverage, weekly feature
stories, and a newsletter to investors who subscribe on PropThink.com. To learn
more visit us at http://www.propthink.com.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: PropThink via Thomson Reuters ONE
[HUG#1635691]
Unternehmensinformation / Kurzprofil:
Datum: 22.08.2012 - 19:02 Uhr
Sprache: Deutsch
News-ID 176902
Anzahl Zeichen: 1911
contact information:
Town:
New York
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 192 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Prana Volume Up on Phase II Trial Updates for Its PBT2 Alzheimer's Candidate"
steht unter der journalistisch-redaktionellen Verantwortung von
PropThink (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
